Brief: Vivesto Says Topline Results For Paccal Vet 'Positive'
15/09/2026 12:54
BRIEF-Vivesto Says Topline Results For Paccal Vet 'Positive' Sept 15 (Reuters) - Vivesto AB VIVE.ST:
ANNOUNCES POSITIVE TOPLINE RESULTS FOR PACCAL VET IN DOGS WITH SPLENIC HEMANGIOSARCOMA
PACCAL VET RESULTED IN A MEDIAN OVERALL SURVIVAL OF 135 DAYS IN DOGS WITH STAGE I-II SPLENIC HEMANGIOSARCOMA FOLLOWING SPLENECTOMY
PACCAL VET SAFETY FINDINGS CONSIDERED TOLERABLE WITH PROACTIVE MONITORING, SUPPORTIVE CARE WHEN NECESSARY
FINAL STUDY RESULTS EXPECTED BY YEAR-END, SUBJECT TO REMAINING DOGS' STATUS
Source text: ID:nMFN932nSc
Further company coverage: VIVE.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Vivesto AB
See all newsBrief: Vivesto Reports Positive Topline Results From Paccal Vet Study In Cats
Brief: Vivesto Says Topline Results For Paccal Vet 'Positive'
Brief: Vivesto Q2 Operating Loss At SEK 8.6 Mln
Brief: Vivesto: Positive Results From Exploratory Study With Cantrixil
Brief: Vivesto Appoints Björn Svanström As CFO